预先授权用于择期浅静脉手术:行政成本高、减少使用效果低
本研究纳入本机构2017年全部1959例门诊下肢浅静脉手术,评估预先授权(PA)的实际效果与成本。结果显示57.9%需PA,仅6.1%初始被拒,近40%拒付经申诉被推翻;拒付带来的付费方节省有限,而行政支出明显更高。结论认为在医师实践已符合保险指南时,PA并非成本有效的利用管理工具。
要点
- 门诊浅静脉手术中约六成需PA,但初始拒付率仅6.1%。
- 近40%的拒付经申诉被推翻,多因资料不全或必要性记录不足。
- PA行政成本超过其带来的付费方节省,成本效益不佳。
核心结论
- 在医师实践已与保险指南良好对齐的前提下,PA对门诊浅静脉手术不是成本有效的利用管理措施。
- 对这类医师和医师团体,PA相关行政成本超过保险公司所见的节省。
研究设计与样本
- 回顾性纳入本机构2017年全部计划开展的门诊下肢静脉手术,共1959例。
- 关注变量包括手术类型、PA初始状态(批准或拒绝)、决定理由及申诉后最终状态。
- 成本分析采用Medicare和Medicaid服务中心允许费率近似账单与报销数据,并按行业平均值计算。
主要发现
- 1959例手术中57.9%(n=1134)需要PA。
- 需PA者中仅6.1%(n=69)初始被拒,近40%(n=27)的拒付经申诉被推翻。
- 42例拒付被维持,其中15例导致手术取消,其余由患者自费(n=11)或医生无偿实施(n=16)。
- 申诉推翻的拒付源于初始PA申请临床资料不完整或临床必要性记录不足。
- 按行业标准计算行政支出超过11万美元,远超同一方法计算的付费方节省。
关键数值与推荐
- 应用Medicare和Medicaid服务中心允许费率时,拒付带来的付费方节省不足6万美元。
- 行政费用按行业标准合计超过11万美元,远超同一方法计算的付费方节省。
- 15例因拒付取消的手术(占全部PA的1.3%)至多近似3万美元的净节省。
临床怎么用
- 对已遵循保险指南的血管外科实践,应预期PA行政负担可能高于其减少使用的收益。
- 针对拒付常见原因,应完善初始PA申请中的临床资料完整性与必要性记录。
- 申诉可挽回相当比例拒付,提示对不合理拒付应积极申诉。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Prior authorization (PA) is a process used by payers for safety and cost savings purposes, but it has received criticism for being time-consuming and costly because of administrative burden. Our study evaluated efficacy of PA applied to in-office lower extremity superficial venous procedures. METHODS: All in-office lower extremity venous procedures scheduled to be performed at our institution in 2017 were included in the study. Variables of interest were type of procedure, initial PA status (approved or denied), rationale for the decision, and final status after appeal. Cost analysis was performed using Centers for Medicare and Medicaid Services allowable rates to approximate billing and reimbursement data (proprietary) as well as calculated using industry averages. RESULTS: For 2017, of 1959 procedures scheduled, 57.9% (n = 1134) required PA. Of these, only 6.1% (n = 69) received initial PA denial, and nearly 40% of the denials (n = 27) were overturned after appeal. Of the 42 denials that were upheld, 15 resulted in cancellations; the remainder were performed by patient self-pay (n = 11) or by the provider pro bono (n = 16). Overturned denials were a result of either submission of incomplete clinical data on initial PA request or insufficient documentation of clinical necessity. When Centers for Medicare and Medicaid Services allowable rates were applied for cost analysis, the denials resulted in <$60,000 payer savings. Administrative expenses totaled >$110,000 when industry standards were applied, which far exceeds any calculated payer savings using the same methods. The 15 denials resulting in procedure cancellations (1.3% of all PAs) could be considered a net savings to the health care system but only approximated a mere $30,000. CONCLUSIONS: Our study demonstrates that PA is not a cost-effective measure for utilization management of outpatient superficial venous procedures when surgeon practices are already well aligned with insurance guidelines. For these physicians and physician groups, the administrative cost associated with the PA process exceeds the savings seen by the insurance companies.
引用
- Lee V, Berland T, Jacobowitz G, et al. Prior authorization as a utilization management tool for elective superficial venous procedures results in high administrative cost and low efficacy in reducing utilization. J Vasc Surg Venous Lymphat Disord. 2019. PMID: 31859243. doi:10.1016/j.jvsv.2019.10.016
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。